Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug darolutamide. The submission, which was initiated in December 2018, is...

from PR Newswire: https://ift.tt/2TmTyGU